The event will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

Contrary to prior data, this study shows that neither eosinophils nor STAT6-mediated IL-4/IL-13 signaling contribute ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been ...

LEO Pharma will be gaining the rights to commercialise Junshi Biosciences’ toripalimab in Europe under a new distribution and ...

Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 26.8% in the past six months against the industry’s decline of ...

As for KT-621, the once-daily oral degrader of STAT6 protein is set to undergo a Phase 1b trial for atopic dermatitis (AD) in Q1, with data expected in Q4 2025. Phase 2b trials for KT-621 in AD ...

Gilead has inked a deal to li­cense Leo Phar­ma’s port­fo­lio of oral STAT6 can­di­dates for in­flam­ma­to­ry dis­eases, less than a month af­ter John­son & John­son … ...

Driven inflammatory disorders like asthma, chronic obstructive pulmonary disease, and atopic dermatitis, the cooperation centers on STAT6, a transcription factor associated with IL-4 and IL-13 ...

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This collaboration aims to develop treatments for patients suffering from inflammatory ...

Gilead agreed to terms on a strategic partnership with LEO Pharma to accelerate the development and commercialization of STAT6, LEO’s small molecule oral program for treating patients with ...

STAT6 is a transcription factor essential for IL-4 and IL-13 cytokine signalling, which are validated targets for Th2 mediated inflammatory conditions such as atopic dermatitis. Credit: ...